Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo

This study thus proposes the everolimus-ABT-737 combination as a novel therapeutic strategy for the treatment of RCC to overcome the current clinical problem of everolimus resistance.

Source: Journal of Cancer - June 13, 2019 Category: Cancer & Oncology Authors: Ayse Hande Nayman, Halime Siginc, Ebru Zemheri, Faruk Yencilek, Asif Yildirim, Dilek Telci Tags: Research Paper Source Type: research